Clinical Trial Update: A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Abiraterone acetate plus low-dose prednisone and androgen deprivation therapy versus ADT alone in newly diagnosed high-risk metastati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2018-10-15